Economic evaluation of cost‐benefit ratio of neonatal screening procedure for phenylketonuria and hypothyroidism

Citations Over TimeTop 19% of 1991 papers

Abstract

A comparison between the cost of identification and care of patients with phenylketonuria (PKU) and congenital hypothyroidism (CH) and the expenditure for the care of untreated retarded patients has been established on the basis of the activity of the Nord-Pas-de-Calais regional screening centre and of interviews with patients' families. The analysis yields a benefit-cost ratio of 6.6 for PKU and 13.8 for CH prophylaxis. However, cost-benefit varies depending on the economic partner, i.e. the patient's family, Social Security or Administration.

Related Papers

• → Cost-Effectiveness of Newborn Screening for Phenylketonuria and Congenital Hypothyroidism(2022)13 cited
• [Screening of newborn infants in Norway for severe metabolic disease].(1995)
• The screening and analysis of congenital hypothyroidism in newborn babies in Jilin(2010)
• Analysis in result of screening for congenital hypothyroidism and phenylketonuria in 638171 neonates(2015)
• Neonatal screening for congenital hypothyroidism(2001)